

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

December 4, 2003

(Use several sheets if necessary)

ATTORNEY DOCKET NO.
3561.1000-007

CONTINUATION APPLICATION OF

~~10/272,510~~ 10/728,340APPLICANT
Dale M. EdgarFILING DATE
December 4, 2003

CONFIRMATION NO.

GROUP
1625

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
<i>CR</i>	AA	5,095,022	10-MAR-92	Ito et al.
<i>J</i>	AB	6,391,890	21-MAY-02	Jorgensen et al.
<i>J</i>	AC	5,153,207	06-OCT-92	Ito, et al.
	AD	4,929,618	29-MAY-90	Koda, et al.
	AE	6,358,944 B1	19-MAR-02	Lederman, et al.
<i>J</i>	AF	6,387,930 B1	14-MAY-02	Baroudy, et al.
	AG			
	AH			
	AJ			
	AJ			
	AK			
	AA2			
	AB2			
	AC2			
	AD2			
	AE2			
	AF2			
	AG2			
	AH2			
	AJ2			
	AK2			
	AA3			
	AB3			
	AC3			

EXAMINER

TM

DATE CONSIDERED

5/10/05

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION December 4, 2003 (Use several sheets if necessary)		ATTORNEY DOCKET NO. 3561.1000-007	CONTINUATION APPLICATION OF 10/272,540 10/288,840
		APPLICANT Dale M. Edgar	
		FILING DATE December 4, 2003	CONFIRMATION NO.
			GROUP 1629

FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
CC	AL	WO 99/00376 A1	07-JAN-99	PCT	
	AM	EP 0 406 739 A2	09-JAN-91	EPO	
	AN	WO 88/09656	15-DEC-88	PCT	
CC	AO	JP 03133956	07-JUN-91	Japan	X
	AP				
	AQ				
	AL2				
	AM2				
	AN2				
	AO2				
	AP2				
	AQ2				
	AL3				
	AM3				
	AN3				
	AO3				
	AP3				
	AQ3				
	AL4				
	AM4				
	AN4				
	AO4				
	AP4				
	AQ4				
	AL5				
	AM5				

EXAMINER /Celia Chang/	DATE CONSIDERED 05/10/2006
-------------------------------	-----------------------------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION		ATTORNEY DOCKET NO. 3561.1000-007	CONTINUATION APPLICATION OF <i>10/777,310 10/728,380</i>
		APPLICANT Dale M. Edgar	
December 4, 2003 (Use several sheets if necessary)		FILING DATE December 4, 2003	CONFIRMATION NO.
			GROUP <i>1628</i>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
CC	AR	Iwasaki, N., et al., "Amphoteric Drugs. II. ¹⁾ Synthesis and Antiallergic Activity of [4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)piperidino]alkanoic Acid Derivatives and Related Compounds," <i>Chem Pharm Bull</i> , 42(11):2285-2290 (1994).	
CC	AS	Iwasaki, et al., "Amphoteric drugs. I. Synthesis and antiallergic activity of [4- (diphenylmethoxy) piperidino] -, [4- (diphenylmethyl) piperazinyl] - and [4- (diphenylmethylene) piperidino] alkanoic acid derivatives," <i>Chemical & Pharmaceutical Bulletin</i> , 42(11): 2276-2284 (1994) . Abstract Accession #: 1995: 441018 HCPLUS.	
CC	AT	Iwasaki, N., et al., "Amphoteric Drugs. I. Synthesis and Antiallergic Activity of [4- (Diphenylmethoxy)piperidino]-, [4(Diphenylmethyl)piperazinyl]- and [4-(Diphenylmethylene) piperidino]alkanoic Acid Derivatives," <i>Chem. Pharm. Bull.</i> , 42(11): 2276-2284 (1994).	
	AU		
	AV		
	AW		
	AX		
	AY		
	AZ		
	AR2		
	AS2		
	AT2		
	AU2		
	AV2		
	AW2		

EXAMINER <i>/Celia Chang/</i>	DATE CONSIDERED <i>05/10/2006</i>
----------------------------------	--------------------------------------



Please type a plus sign (+) in this box +

NOV 09 2004

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)					Application Number	10/728,340		
					Filing Date	December 12, 2003		
					First Named Inventor	Edgar		
					Group Art Unit	1625		
					Examiner Name	Celia C. Chang		
					Attorney Docket Number	20712-501 CON		
U.S. PATENT DOCUMENTS								
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate	
CC	*A1	4,383,999	05/17/83	Bondinell et al.	424	266		
	*A2	4,514,414	04/30/85	Bondinell et al.	514	422		
	*A3	4,610,995	09/09/86	Coker et al.	514	343		
	*A4	4,931,450	06/05/90	Sonnewald	514	326		
	*A5	5,225,559	07/06/93	Kita et al.	546	194		
	*A6	5,231,105	07/27/93	Shoji et al.	514	325		
	*A7	5,801,175	09/01/98	Afonso et al.	514	254		
	*A8	6,054,458	04/25/00	Jørgensen et al.	514	255		
	*A9	6,174,898 B1	01/16/01	Weis et al.	514	315		
	*A10	6,191,165 B1	02/20/01	Ognyanov et al.	514	523		
	*A11	6,214,827 B1	04/10/01	Afonson et al.	514	252.13		
	*A12	6,288,083 B1	09/11/01	Luly et al.	514	318		
	*A13	6,288,084 B1	09/11/01	Luly et al.	514	318		
	*A14	6,307,052 B1	10/23/01	Kita et al.	546	194		
CC	*A15	6,503,926 B2	01/07/03	Luly et al.	514	318		
U.S. PUBLISHED APPLICATION DOCUMENTS								
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate	
FOREIGN PATENT DOCUMENTS								
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)		Date of Publication	Translation Yes No		
CC	*B1	WO 95/01350	SUMITOMO METAL INDUSTRIES, LTD.		01/12/95			
	*B2	WO 96/31478	SCHERING CORPORATION; PHARMACOPEIA, INC.		10/10/96			
	*B3	WO 97/45115	TROPHIX PHARMACEUTICALS, INC.		12/04/97			
	*B4	WO 00/14084	WANNER, KLAUS		03/16/00	Abstract only		
	*B5	WO 03/033489 A1	STC NARA CO., LTD.		04/24/03			
	*B6	EP 0 335 586 A1	UBE INDUSTRIES, LTD.		10/04/89			
	*B7	EP 0 399 414 A1	HOKURIKU PHARMACEUTICALS CO., LTD		11/28/90			
CC	*B8	EP 0 949 260 B1	UBE INDUSTRIES, LTD; TANABE SEIYAKU CO., LTD.		10/13/99			

CC	*B9	JP	05-17442 A	HOKURIKU SEIYAKU CO., LTD	01/26/93	Abstract only	
	*B10	JP	05-17443 A2	HOKURIKU SEIYAKU CO., LTD	01/26/93	Abstract only	
	*B11	JP	05-294929 A	UBE IND. LTD	11/09/93	Abstract only	
	*B12	JP	2001-261553 A	TANABE SEIYAKU CO; UBE IND. LTD.	09/26/01	Abstract only	
CC	*B13	JP	2004-051600 A2	IYAKU BUNSHI SEKKEI KENKYUSHO:KK; OSAKA BIOSCIENCE INSTITUTE	02/19/04	Abstract only	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
CC	*C1	Andersen et al. <i>J. Med. Chem.</i> , 36(12):1716-1725 (1993)
	*C2	Andersen et al. <i>J. Med. Chem.</i> , 42:4281-4291 (1999)
	*C3	Dhar et al. <i>Bioorg. Med. Chem. Lett.</i> , 6(13):1535-1540 (1996)
	*C4	Falch et al. <i>Eur. J. Med. Chem.</i> , 26:69-78 (1991)
	*C5	Iwasaki et al. <i>Chem. Pharm. Bull.</i> , 42(11):2276-2284 (1994)
	*C6	Iwasaki et al. <i>Chem. Pharm. Bull.</i> , 42(11):2285-2290 (1994)
	*C7	Muramatsu et al. <i>Chem. Pharm. Bull.</i> , 41(11):1987-1993 (1993)
	*C8	N'Goka et al. <i>J. Med. Chem.</i> , 34(8):2547-2557 (1991)
	*C9	Ohshima et al. <i>J. Med. Chem.</i> , 35(11):2074-2084 (1992)
	*C10	Patani et al. <i>Chem. Rev.</i> , 96(8):3147-3176 (1996)
CC	*C11	Yunger et al. <i>J. Pharmacol. Exp. Ther.</i> , 228(1):109-115 (1984)

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/272,510, filed October 16, 2002, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Celia Chang/	Date Considered	05/23/2006
--------------------	---------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.